User login
Key clinical point: Infliximab de-escalation is safe and well tolerated in patients with Crohn’s disease (CD) in clinical remission and with supratherapeutic trough levels.
Major finding: More than half of the patients had a trough level of 10 ug/mL or higher at baseline. Trough levels were not significant among patients de-escalating to 5 mg/kg and 3 mg/kg at the final infusion (11.9 vs 9.2, respectively; P = .55). At the final visit, all patients were in clinical remission and remained on their de-escalated dose.
Study details: This was a prospective pilot trial of 52 patients with CD in clinical remission on infliximab at a consistent dose for at least 1 year. Thirteen and 6 patients de-escalated from 10/7.5 mg/kg to 5 mg/kg and from 5 mg/kg to 3 mg/kg, respectively.
Disclosures: No source of funding was declared. JR Allegretti and MJ Hamilton declared serving as a consultant and receiving grant support from various sources.
Source: Allegretti JR et al. Inflamm Bowel Dis. 2021 Jun 18. doi: 10.1093/ibd/izab131.
Key clinical point: Infliximab de-escalation is safe and well tolerated in patients with Crohn’s disease (CD) in clinical remission and with supratherapeutic trough levels.
Major finding: More than half of the patients had a trough level of 10 ug/mL or higher at baseline. Trough levels were not significant among patients de-escalating to 5 mg/kg and 3 mg/kg at the final infusion (11.9 vs 9.2, respectively; P = .55). At the final visit, all patients were in clinical remission and remained on their de-escalated dose.
Study details: This was a prospective pilot trial of 52 patients with CD in clinical remission on infliximab at a consistent dose for at least 1 year. Thirteen and 6 patients de-escalated from 10/7.5 mg/kg to 5 mg/kg and from 5 mg/kg to 3 mg/kg, respectively.
Disclosures: No source of funding was declared. JR Allegretti and MJ Hamilton declared serving as a consultant and receiving grant support from various sources.
Source: Allegretti JR et al. Inflamm Bowel Dis. 2021 Jun 18. doi: 10.1093/ibd/izab131.
Key clinical point: Infliximab de-escalation is safe and well tolerated in patients with Crohn’s disease (CD) in clinical remission and with supratherapeutic trough levels.
Major finding: More than half of the patients had a trough level of 10 ug/mL or higher at baseline. Trough levels were not significant among patients de-escalating to 5 mg/kg and 3 mg/kg at the final infusion (11.9 vs 9.2, respectively; P = .55). At the final visit, all patients were in clinical remission and remained on their de-escalated dose.
Study details: This was a prospective pilot trial of 52 patients with CD in clinical remission on infliximab at a consistent dose for at least 1 year. Thirteen and 6 patients de-escalated from 10/7.5 mg/kg to 5 mg/kg and from 5 mg/kg to 3 mg/kg, respectively.
Disclosures: No source of funding was declared. JR Allegretti and MJ Hamilton declared serving as a consultant and receiving grant support from various sources.
Source: Allegretti JR et al. Inflamm Bowel Dis. 2021 Jun 18. doi: 10.1093/ibd/izab131.